Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAFV600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison

Puntos clave

• Encorafenib plus binimetinib (E + B) resulted in longer progression-free survival compared to dabrafenib plus trametinib (D + T), indicating effectiveness.
• The treatment with E + B was associated with fewer serious adverse events, enhancing its safety profile.
• This analysis employed a matching-adjusted indirect treatment comparison to evaluate the two regimens effectively.
• The findings support considering E + B as a promising first-line treatment option for patients with BRAF V600E-mutant metastatic non-small cell lung cancer.